Afficher la couverture 'High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia | Durot, Eric' en grand format
/5

0 avis

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Archive ouverte

Durot, Eric | Roos-Weil, Damien | Chauchet, Adrien | Decroocq, Justine | Di Blasi, Roberta | Gastinne, Thomas | Bensaber, Hedi | Cheminant, Morgane | Jacquet, Caroline | Guidez, Stéphanie | Gros, François-Xavier | Bachy, Emmanuel | Coste, Arthur | Cony-Makhoul, Pascale | Treon, Steven | Delmer, Alain | Reshef, Ran | Le Gouill, Steven | Castillo, Jorge | Houot, Roch

Edité par CCSD ; American Society of Hematology -

International audience. Abstract Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a high efficacy and no unexpected toxicity.

Suggestions

Du même auteur

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Archive ouverte | Durot, Eric | CCSD

International audience. Introduction: Patients with histological transformation (HT) of Waldenström macroglobulinemia (WM) who relapse or are refractory (R/R) have a poor prognosis with standard chemoimmunotherapy, ...

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry

Archive ouverte | Galtier, Jean | CCSD

International audience. Primary mediastinal B-cell lymphoma (PMBL) is often cured with dose-dense anthracycline-based regimens but the prognosis at relapse or progression remains poor. While anti-CD19 CAR-T cell the...

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Archive ouverte | Di Blasi, Roberta | CCSD

International audience. Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant number of patients expe...

Chargement des enrichissements...